Evidence map›Paper›PMID 35451016›Full record

ArticleDevelopment (Cambridge, England)2022

GDF5+ chondroprogenitors derived from human pluripotent stem cells preferentially form permanent chondrocytes.

Azim Pothiawala, Berke E Sahbazoglu, Bryan K Ang, Nadine Matthias, Guangsheng Pei, Qing Yan, Brian R Davis, Johnny Huard, Zhongming Zhao, Naoki Nakayama

Open access · bronzeAbstract read
In one paragraph

Article in Development (Cambridge, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Azim PothiawalaInstitute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Berke E SahbazogluInstitute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Bryan K AngInstitute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Nadine MatthiasInstitute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Guangsheng PeiCenter for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Qing YanInstitute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Brian R DavisInstitute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Johnny HuardDepartment of Orthopedic Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Zhongming ZhaoCenter for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.ORCID 0000-0002-3477-0914
Naoki NakayamaInstitute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.ORCID 0000-0002-6315-4387
The University of Texas Health Science Center at Houston · USSteadman Philippon Research Institute · US

Funding

Rare mutations in Cystic Fibrosis: Overcoming barriers to personalized medicineR01HL139876 · NHLBI · EMORY UNIVERSITY · PI DAVIS, BRIAN R., SORSCHER, ERIC J · 2018 to 2022
$3.8M
Transforming dbGaP genetic and genomic data to FAIR-ready by artificial intelligence and machine learning algorithmsR01LM012806 · NLM · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Zhongming Zhao · 2017 to 2026
$3.7M
Articular Cartilage Tissue Engineering with Human Pluripotent Stem CellsR01AR077045 · NIAMS · STEADMAN PHILIPPON RESEARCH INSTITUTE · PI NAKAYAMA, NAOKI · 2021 to 2025
$1.7M
Muscle Stem Cells Reprogrammed Through Genome Engineering for Autonomously Regulated Anti-Fibrotic TherapyR21AR072870 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GUILAK, FARSHID, HUARD, JOHNNY · 2018 to 2019
$416k
SMART stem cells that autonomously down-modulate TFG-β signaling for Articular Cartilage RepairR21AR079075 · NIAMS · STEADMAN PHILIPPON RESEARCH INSTITUTE · PI GUILAK, FARSHID, HUARD, JOHNNY · 2022 to 2023
$376k
Effects of Circulating Factors and Progenitors on Wound Healing during PregnancyR21AR073509 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HUARD, JOHNNY · 2018 to 2019
$375k
Ablation of Non-Myogenic Progenitor Cells as a New Therapeutic Approach to Duchenne Muscular DystrophyR21AR074132 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HUARD, JOHNNY, KOLONIN, MIKHAIL G · 2019 to 2020
$343k
Development of biological approaches to enhance skeletal muscle rehabilitation after anterior cruciate ligament injuryR21AR075997 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HUARD, JOHNNY, NARKAR, VIHANG A · 2019 to 2020
$332k
NHLBI NIH HHS R01 HL139876NIAMS NIH HHS R01 AR077045NIAMS NIH HHS R21 AR072870NIAMS NIH HHS R21 AR073509NIAMS NIH HHS R21 AR074132NIAMS NIH HHS R21 AR075997NIAMS NIH HHS R21 AR079075NLM NIH HHS R01 LM012806
6 · The paper itself

Abstract

It has been established in the mouse model that during embryogenesis joint cartilage is generated from a specialized progenitor cell type, distinct from that responsible for the formation of growth plate cartilage. We recently found that mesodermal progeny of human pluripotent stem cells gave rise to two types of chondrogenic mesenchymal cells in culture: SOX9+ and GDF5+ cells. The fast-growing SOX9+ cells formed in vitro cartilage that expressed chondrocyte hypertrophy markers and readily underwent mineralization after ectopic transplantation. In contrast, the slowly growing GDF5+ cells derived from SOX9+ cells formed cartilage that tended to express low to undetectable levels of chondrocyte hypertrophy markers, but expressed PRG4, a marker of embryonic articular chondrocytes. The GDF5+-derived cartilage remained largely unmineralized in vivo. Interestingly, chondrocytes derived from the GDF5+ cells seemed to elicit these activities via non-cell-autonomous mechanisms. Genome-wide transcriptomic analyses suggested that GDF5+ cells might contain a teno/ligamento-genic potential, whereas SOX9+ cells resembled neural crest-like progeny-derived chondroprogenitors. Thus, human pluripotent stem cell-derived GDF5+ cells specified to generate permanent-like cartilage seem to emerge coincidentally with the commitment of the SOX9+ progeny to the tendon/ligament lineage.

Indexed as

Cartilage, ArticularChondrocytesPluripotent Stem CellsAnimalsCell DifferentiationChondrogenesisGrowth Differentiation Factor 5HumansHypertrophyMiceGDF5 protein, humanGdf5 protein, mouseGrowth Differentiation Factor 5Articular cartilageChondrocyteHypertrophyInterzoneJointLigamentMineralizationParaxial mesodermPluripotent stem cell

Identifiers

PMID35451016
PMCPMC9245189
OpenAlexW4224211211

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.